Evaluation of PD1 and PD-L1 expression in high-grade sarcomas of the limbs in the adults: possible implications of immunotherapy

C. Perisano, R. Vitiello, A. Sgambato, T. Greco, L. Cianni, G. Ragonesi, T. Malara, G. Maccauro, M. Martini

Article ID: 5652
Vol 34, Issue 4S3, 2020
DOI: https://doi.org/10.54517/jbrha5652
Received: 8 September 2020; Accepted: 8 September 2020; Available online: 8 September 2020; Issue release: 8 September 2020

Abstract

Sarcomas are a heterogeneous group of rare tumours. Improvements in immunotherapy and the important role of PD1 and PD-L1 expression in advancement and prognosis have opened new fields of research for the treatment of these neoplasia. We evaluated the immunohistochemistry of PD1 and PD-L1 expression in 60 adults patients affected by high-grade sarcomas of the limbs. PD1 expression was 65% while PD-L1 was 68.3%. PD-L1 expression seems to correlate to Ki67 in liposarcomas, fibrosarcomas and pleomorphic sarcomas, while it does not show any correlation to chondrosarcomas, while in rhabdomyosarcomas there is a correlation but, given the small sample size, it was not possible to perform a statistic analysis. Our study shows positivity among the different subgroups of positive PD1 lymphocytes infiltration and PD-L1 expression in high-grade sarcomas of the limbs.


Keywords

sarcoma;immunotherapy;programmed cell death receptor;PD;PD-L1


References

Supporting Agencies



Copyright (c) 2020 C. Perisano, R. Vitiello, A. Sgambato, T. Greco, L. Cianni, G. Ragonesi, T. Malara, G. Maccauro, M. Martini




This site is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).